| TITLE |
DATE |
| POZEN Monetizes Its Treximet Royalty Stream for $75 Million |
28-Nov-2011 |
| POZEN to Present at the Piper Jaffray 23rd Annual Healthcare Conference |
17-Nov-2011 |
| Positive Results from POZEN Phase 1 Study ("Co-Rx") Presented At AHA |
14-Nov-2011 |
| Pozen to Present at the Lazard Capital Markets' 8th
Annual Healthcare Conference |
9-Nov-2011 |
| POZEN To Participate in the Brean Murray Carret & Co. 2011 Life
Sciences Summit |
8-Nov-2011 |
| POZEN Reports Third Quarter 2011 Results |
3-Nov-2011 |
| POZEN Announces November 3, 2011 Webcast of Third Quarter 2011 Results |
20-Oct-2011 |
| POZEN Reports Top-Line Data from Long-Term Safety Study of PA32540 |
13-Oct-2011 |
| POZEN Provides Patent Litigation and Financial Guidance Update |
4-Oct-2011 |
| POZEN Announces Engaging Keelin Reeds Partners LLC to Assist With
PA32540 Strategic Partner Search |
3-Oct-2011 |
| POZEN Announces October 4, 2011 Mid-Quarter Update and Financial
Guidance Webcast |
27-Sep-2011 |
| POZEN To Present at the 2011 UBS Global Life Sciences Conference |
8-Sep-2011 |
| POZEN to Present at the 2011 Stifel Nicolaus Healthcare Conference |
24-Aug-2011 |
| POZEN Welcomes Clint Burrus as Vice President, Customer Development |
16-Aug-2011 |
| Pozen Patents Upheld in Treximet Patent Litigation |
8-Aug-2011 |
| POZEN Reports Second Quarter 2011 Results |
28-Jul-2011 |
| POZEN Welcomes Dr. Seth A. Rudnick to the Board of Directors |
27-Jul-2011 |
| POZEN Forms Unprecedented Advisory Board of Digital Thought-Leaders
to Advance Commercial Plans |
19-Jul-2011 |
| POZEN Announces July 28, 2011 Webcast of Second Quarter 2011 Results |
14-Jul-2011 |
| POZEN Announces Tomas S. Bocanegra, M.D. as Head of Development |
12-Jul-2011 |
| POZEN Announces Election of Dr. Martin Nicklasson to the Board of
Directors |
16-Jun-2011 |
| POZEN to Present at The UBS Specialty Pharmaceuticals Conference |
15-Jun-2011 |
| POZEN to Present at the 2011 Wells Fargo Securities Healthcare Conference |
9-Jun-2011 |
| POZEN Ranked as Second Most Efficient Pharma Company by SmarTrend |
25-May-2011 |
| POZEN to Present at the Jefferies 2011 Global Life Sciences Conference |
24-May-2011 |
| POZEN Reports First Quarter 2011 Results |
5-May-2011 |
| AstraZeneca and POZEN File Patent Infringement Lawsuit Against Dr.
Reddy's |
25-Apr-2011 |
| POZEN Announces May 5, 2011 Webcast of First Quarter 2011 Results |
21-Apr-2011 |
| Preliminary Injunction Ordered in POZEN Treximet Patent Litigation |
15-Apr-2011 |
| POZEN Reports Superior Platelet Inhibition of PA32540 Regimen Over a
Standard of Care Regimen in a Phase 1 Study ("Co-Rx") |
24-Mar-2011 |
| POZEN To Present at the 10th Annual Needham
Healthcare Conference |
24-Mar-2011 |
| POZEN Announces Licensing Deal with Cilag GmbH, A Division of Johnson
& Johnson, for MT 400, Migraine Treatment |
23-Mar-2011 |
| POZEN Files Motion for Preliminary Injunction in Treximet Patent
Litigation |
22-Mar-2011 |
| POZEN Reports Fourth Quarter and Year End 2010 Results |
9-Mar-2011 |
| POZEN Announces March 9, 2011 Webcast of Fourth Quarter & Year End 2010 Results |
24-Feb-2011 |
| POZEN to Present at the Cowen and Company 31st
Annual Healthcare Conference |
23-Feb-2011 |
| POZEN Announces Addition to Commercial Team |
22-Feb-2011 |
| POZEN to Present at the 22nd Annual Piper
Jaffray Healthcare Conference |
19-Nov-2010 |
| POZENPA32540 Phase 1 Data Presented at The American
Heart Association Scientific Sessions |
14-Nov-2010 |
| POZEN Announces Achievement of $25 Million Milestone For VIMOVO(TM) |
12-Nov-2010 |
| POZEN Statement on FDA Gastrointestinal Drugs Advisory Committee
Meeting |
5-Nov-2010 |
| Three POZEN Projects Selected for Therapeutic Discovery Grants |
2-Nov-2010 |
| POZEN Reports Third Quarter 2010 Results |
28-Oct-2010 |
| POZEN Announces October 28, 2010 Webcast of Third Quarter 2010 Results |
14-Oct-2010 |
| Positive Agreement Received For Approval of Vimovo In Europe |
11-Oct-2010 |
| POZEN To Present at the UBS 2010 Global Life Sciences Conference |
8-Sep-2010 |
| POZEN Reports Second Quarter Profit; Results Reflect $20 Million Milestone Payment For VIMOVO(TM) |
3-Aug-2010 |
| POZEN To Present at The BMO Capital Markets Focus on Healthcare
Conference |
22-Jul-2010 |
| POZEN Announces August 3, 2010 Webcast of Second Quarter 2010 Results |
21-Jul-2010 |
| POZEN to Present at the Wells Fargo Securities 3rd Annual Healthcare Conference |
16-Jun-2010 |
| POZEN Announces Election of Neal F. Fowler to the Board of Directors |
15-Jun-2010 |
| POZEN To Present at the Jefferies 2010 Global Life Sciences Conference |
27-May-2010 |
| POZEN Announces Receipt of $20 Million Milestone Payment from
AstraZeneca |
25-May-2010 |
| POZEN Reports PA65020 Significantly Reduces the Incidence of Upper GI
Damage in Healthy Adults |
6-May-2010 |
| REPEAT/POZEN Announces May 3, 2010 Webcast |
3-May-2010 |
| FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers |
30-Apr-2010 |
| POZEN Announces May 3, 2010 Webcast |
30-Apr-2010 |
| POZEN Reports First Quarter 2010 Results |
29-Apr-2010 |
| POZEN Announces April 29, 2010 Webcast of First Quarter 2010 Results |
21-Apr-2010 |
| POZEN Enters into Settlement Agreement With Teva Regarding Paragraph IV Patent Litigation |
14-Apr-2010 |
| POZEN Reports Fourth Quarter/Year End 2009 Results |
3-Mar-2010 |
| POZEN Announces March 3, 2010 Webcast of Fourth Quarter and Year End
2009 Results |
24-Feb-2010 |
| POZEN to Present at the Cowen & Company 30th
Annual Healthcare Conference |
22-Feb-2010 |
| POZEN To Present at the Brean Murray Carret & Co. Boston Healthcare
Conference |
16-Feb-2010 |
| POZEN to Host Investor and Analyst Event on December 8, 2009 |
3-Dec-2009 |
| POZEN Announces Start of Enrollment For PA32540 Phase 3 Program |
20-Nov-2009 |
| POZEN To Present at the Credit Suisse Healthcare Conference |
30-Oct-2009 |
| POZEN Reports Third Quarter 2009 Results |
28-Oct-2009 |
| Results of Phase I Study Show Novel, Investigational PA65020 Compound Significantly Decreased Risk of Upper GI Damage in Healthy Adults |
27-Oct-2009 |
| Patients taking VIMOVO showed improved UGI tolerability assessments as compared to EC naproxen |
27-Oct-2009 |
| Patients Taking VIMOVO(TM) Showed Decrease in incidence of NSAID Associated Ulcers |
19-Oct-2009 |
| AstraZeneca Submits Marketing Authorisation Application to European Union for VIMOVO™ |
16-Oct-2009 |
| POZEN Announces October 28, 2009 Webcast of Third Quarter 2009 Results |
14-Oct-2009 |
| POZEN Inc. Announces Federal District Court Grants Motion to Dismiss Securities Class Action Lawsuit |
30-Sep-2009 |
| POZEN Names Elizabeth A. Cermak as Executive Vice President, Chief Commercial Officer |
14-Sep-2009 |
| POZEN To Present at the UBS Global Life Sciences Conference |
9-Sep-2009 |
| POZEN Announces FDA Acceptance of NDA For VIMOVO(TM) |
31-Aug-2009 |
| POZEN To Present at the Thomas Weisel Partners 2009 Healthcare Conference |
27-Aug-2009 |
| POZEN Reports Second Quarter 2009 Results |
28-Jul-2009 |
| POZEN To Present at the 2009 BMO Capital Markets Focus on Healthcare Conference |
22-Jul-2009 |
| POZEN Announces July 28, 2009 Webcast of Second Quarter 2009 Results |
14-Jul-2009 |
| POZEN Submits New Drug Application For VIMOVO(TM) (PN 400) |
30-Jun-2009 |
| POZEN Announces Election of Angela M. Larson to Board of Directors |
9-Jun-2009 |
| POZEN Receives Decision from AstraZeneca to File PN 400 NDA |
13-May-2009 |
| POZEN Reports First Quarter 2009 Results |
30-Apr-2009 |
| POZEN Announces April 30, 2009 Webcast of First Quarter 2009 Results |
16-Apr-2009 |
| POZEN To Present at the Citi Annual Biotech Day |
19-Mar-2009 |
| POZEN to Present at the Cowen and Company 29th Annual Healthcare Conference |
4-Mar-2009 |
| POZEN Reports Fourth Quarter and Year End 2008 Results |
25-Feb-2009 |
| POZEN Announces February 25, 2009 Webcast of Fourth Quarter and Year End 2008 Results |
11-Feb-2009 |
| POZEN Informed by FDA That Endoscopic Gastric Ulcer Incidence Continues to Be an Acceptable Primary Endpoint |
29-Jan-2009 |
| POZEN Announces Positive Top Line Results for Its PN 400 Phase 3 Trials |
3-Dec-2008 |
| POZEN To Participate in The RBC Capital Markets 2008 Healthcare Conference |
2-Dec-2008 |
| POZEN'S PA32520 Study Data Demonstrated Better Upper Gastrointestinal Protection |
11-Nov-2008 |
| POZEN Reports Third Quarter 2008 Results |
29-Oct-2008 |
| POZEN Announces October 29, 2008 Webcast of Third Quarter 2008 Results |
22-Oct-2008 |
| POZEN Confirms ANDA Filing for Treximet(R) Tablets |
17-Oct-2008 |
| POZEN Informed of FDA Internal Review of Gastric Ulcers as a Primary Endpoint in Clinical Trials |
17-Oct-2008 |
| POZEN To Present at The UBS Life Sciences Conference |
10-Sep-2008 |
| POZEN Sponsors Habitat for Humanity Home in Hillsborough, North Carolina |
8-Sep-2008 |
| POZEN To Present at the 3rd Annual Citi Biotech Day |
26-Aug-2008 |
| POZEN Receives Initial FDA Response To PA32540 SPA |
1-Aug-2008 |
| POZEN Reports Second Quarter 2008 Results |
29-Jul-2008 |
| POZEN to Present at the 2008 BMO Capital Markets Focus on Healthcare Conference |
24-Jul-2008 |
| POZEN Announces July 29, 2008 Webcast of Second Quarter 2008 Results |
15-Jul-2008 |
| POZEN To Present at the Jefferies 2nd Annual Healthcare Conference |
16-Jun-2008 |
| POZEN Demonstrates Bioequivalence to Enteric Coated Aspirin for PA32540 |
9-Jun-2008 |
| POZEN To Present at the Seventh Annual Needham & Co., LLC Biotechnology & Medical Technology Conference |
2-Jun-2008 |
| POZEN Announces PN 200 Podium Presentation at Digestive Disease Week |
19-May-2008 |
| POZEN To Present at the Citigroup Global Healthcare Conference |
15-May-2008 |
| POZEN IND and NDA for Treximet(TM) (Sumatriptan/Naproxen Sodium) Transferred to GlaxoSmithKline |
14-May-2008 |
| POZEN Reports First Quarter 2008 Results |
8-May-2008 |
| POZEN To Present at Baird's 2008 Growth Stock Conference |
1-May-2008 |
| POZEN Announces Receipt of $20 Million in Milestone Payments from GlaxoSmithKline |
28-Apr-2008 |
| POZEN Announces May 8, 2008 Webcast of First Quarter 2008 Results |
25-Apr-2008 |
| Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine |
15-Apr-2008 |
| POZEN To Present at the Cowen and Company 28th Annual Healthcare Conference |
4-Mar-2008 |
| POZEN Reports Fourth Quarter and Year End 2007 Results |
26-Feb-2008 |
| POZEN's Dr. William Kelce Appointed Adjunct Associate Professor at UNC, Chapel Hill |
21-Feb-2008 |
| POZEN to Present at the Susquehanna Financial Group's Second Annual Significant Options in Healthcare Conference |
14-Feb-2008 |
| POZEN Announces February 26, 2008 Webcast of Fourth Quarter and Full Year 2007 Results |
12-Feb-2008 |
| POZEN to Present at the Wachovia Securities 2008 Small & Mid Cap Healthcare Conference |
16-Jan-2008 |
| POZEN Submits Human Lymphocyte Study for Treximet(TM) (Formerly Known as Trexima(TM)) |
15-Jan-2008 |
| POZEN to Present at the RBC Capital Markets 2007 Healthcare Conference |
28-Nov-2007 |
| POZEN To Present at the BMO Capital Markets 2007 Focus on Healthcare Conference |
26-Nov-2007 |
| POZEN To Present at the Lazard Capital Markets Fourth Annual Healthcare Conference |
14-Nov-2007 |
| Pozen Announces Trexima(TM) (Sumatriptan Succinate and Naproxen Sodium) Amended Response Accepted for Review by FDA |
1-Nov-2007 |
| POZEN Reports Third Quarter Results |
1-Nov-2007 |
| POZEN Announces November 1, 2007 Webcast of Third Quarter 2007 Results |
17-Oct-2007 |
| POZEN Submits Response to Approvable Letter for Trexima(TM) |
15-Oct-2007 |
| POZEN Plans to Submit Response to Approvable Letter For Trexima(TM) Within the Next Ten Days |
5-Oct-2007 |
| POZEN Announces September 7, 2007 Webcast |
7-Sep-2007 |
| POZEN/AstraZeneca Announce Start of the PN 400 Phase III Program |
7-Sep-2007 |
| Pozen Announces August 2, 2007, Webcast |
2-Aug-2007 |
| FDA Issues Second Approvable Letter for Trexima (TM) |
2-Aug-2007 |
| POZEN Reports Second Quarter 2007 Results |
26-Jul-2007 |
| POZEN Names Dr. John G. Fort as Chief Medical Officer |
24-Jul-2007 |
| POZEN Announces July 26, 2007 Webcast of Second Quarter 2007 Results |
16-Jul-2007 |
| POZEN Announces Settlement Agreement in Shareholder Lawsuit |
10-Jul-2007 |
| POZEN to Present at the Jefferies 2007 Healthcare Conference |
14-Jun-2007 |
| POZEN to Present at the Needham Sixth Annual Biotechnology & Medical Technology Conference |
31-May-2007 |
| POZEN To Present at Citigroup's Global Healthcare Conference |
14-May-2007 |
| POZEN Reports First Quarter 2007 Results |
2-May-2007 |
| POZEN to Present at the Baird 2007 Growth Stock Conference |
1-May-2007 |
| POZEN To Present at the 2007 UBS Global Generic and Specialty Pharmaceuticals Conference |
30-Apr-2007 |
| POZEN Announces May 2, 2007 Webcast of First Quarter 2007 Results |
18-Apr-2007 |
| Trexima (TM) (Sumatriptan/Naproxen Sodium) Superior Efficacy Data Published in JAMA |
3-Apr-2007 |
| POZEN Announces Trexima(TM) (Sumatriptan Succinate and Naproxen Sodium) Amended Response Accepted for Review by FDA |
22-Mar-2007 |
| POZEN to Present at the 27th Annual Cowen & Company Healthcare Conference |
12-Mar-2007 |
| POZEN Reports Fourth Quarter and Year End 2006 Results |
7-Mar-2007 |
| POZEN Announces Positive Outcome for PA 325 Proof of Concept Study |
6-Mar-2007 |
| POZEN To Present at the Oppenheimer Conference ''Positioning Investors for the Next Wave in Pain Management'' |
28-Feb-2007 |
| POZEN To Present at the Susquehanna Financial Group Healthcare Conference |
16-Feb-2007 |
| Jacques Rejeange Appointed to POZEN Board of Directors |
15-Feb-2007 |
| POZEN Announces March 7 Webcast of Fourth Quarter and Full Year 2006 Results |
14-Feb-2007 |
| POZEN to Present at the Wachovia Securities 2007 Small and Mid-Cap Healthcare Conference |
17-Jan-2007 |
| POZEN Names Gilda M. Thomas as Senior Vice President and General Counsel |
10-Jan-2007 |
| Pozen Expects to Submit Revised Response to Trexima(TM) (Sumatriptan/Naproxen Sodium) Approvable Letter by Year End |
13-Dec-2006 |
| POZEN To Present at the 2006 RBC Capital Markets Healthcare Conference |
7-Dec-2006 |
| POZEN to Present at the BMO 6th Annual Investor Conference - Focus on Healthcare |
30-Nov-2006 |
| POZEN to Present at the Lazard Capital Markets Third Annual Life Sciences Conference |
21-Nov-2006 |
| POZEN Submits Full Response to FDA Approvable Letter For Trexima™ |
9-Nov-2006 |
| POZEN to Present at the Cowen & Company 7th Annual Global Health Care Conference |
1-Nov-2006 |
| POZEN Reports Third Quarter 2006 Results |
31-Oct-2006 |
| POZEN To Ring NASDAQ Closing Bell |
23-Oct-2006 |
| POZEN Announces October 31 Webcast of Third Quarter 2006 Results |
17-Oct-2006 |
| POZEN Announces Receipt of $40 Million Upfront Payment from AstraZeneca; Company Provides Revised 2006 Guidance |
21-Sep-2006 |
| New Analysis Shows Patients Who Treat Their Migraine Pain Early With Trexima™ (Sumatriptan Succinate/Naproxen Sodium) Have Higher Sustained Pain-Free Rates Than Those Who Treat Late |
20-Sep-2006 |
| New Data Show Consistent Efficacy and Tolerability of Trexima™ (Sumatriptan Succinate/Naproxen Sodium) Across Multiple Migraine Attacks |
20-Sep-2006 |
| New Data Show Peak Concentration of Sumatriptan Occurred Earlier With Trexima™ (Sumatriptan Succinate/Naproxen Sodium) Compared to Imitrex® (Sumatriptan Succinate) |
20-Sep-2006 |
| POZEN To Present at the UBS 2006 Global Life Sciences Conference |
13-Sep-2006 |
| POZEN To Present at the Bear Stearns 19th Annual Healthcare Conference |
5-Sep-2006 |
| Pozen Reports Second Quarter 2006 Results |
3-Aug-2006 |
| POZEN and AstraZeneca Announce Global Collaboration to Co-Develop and Commercialize Fixed Dose Combinations of Naproxen and Esomeprazole for the Treatment of Pain |
2-Aug-2006 |
| POZEN to Submit Full Response to Trexima™ Approvable Letter During the Fourth Quarter |
31-Jul-2006 |
| POZEN Announces August 3 Webcast of Second Quarter 2006 Results |
25-Jul-2006 |
| New Data Show Investigational Migraine Therapy Demonstrates Effective Treatment of Migraine-Associated Neck and Sinus Pain |
26-Jun-2006 |
| New Data Demonstrate Sustained Efficacy of Single Tablet Combination Migraine Therapy Compared to Monotherapy |
26-Jun-2006 |
| POZEN Inc. and Glaxosmithkline Report Receipt of Approvable Letter for Investigational Migraine Treatment |
9-Jun-2006 |
| POZEN Reports First Quarter 2006 Results |
27-Apr-2006 |
| POZEN Announces Completion of Special Protocol Assessment for PN 200; New Arthritis Product Phase III Trials to Begin on Schedule |
20-Apr-2006 |
| POZEN Announces April 27 Webcast of First Quarter 2006 Results |
13-Apr-2006 |
| New Data Presented on Satisfaction, Productivity and Long-Term Safety of a Single Tablet Containing Sumatriptan Formulated With RT Technology(TM) and Naproxen Sodium |
5-Apr-2006 |
| New Pivotal Trial Data Demonstrated Superior Clinical Benefits of Single Tablet Containing Sumatriptan Formulated With RT Technology(TM) and Naproxen Sodium |
5-Apr-2006 |
| POZEN to Present at the SunTrust Robinson Humphrey 35th Annual Institutional Conference |
4-Apr-2006 |
| POZEN Announces Changes to Its Board of Directors; The Company Appoints Donald H. Namm and James J. Mauzey and Accepts the Resignations of Ted G. Wood and James R. Butler |
16-Mar-2006 |
| POZEN to Present at Cowen & Co. 26th Annual Health Care Conference |
2-Mar-2006 |
| POZEN Reports Fourth Quarter and Year End 2005 Results; $20 Million Milestone Payment from GSK Contributes to Profitability; Lornoxicam Phase II Studies Initiated in Acute Pain And Migraine |
1-Mar-2006 |
| POZEN Announces Change of Date for Webcast of Fourth Quarter and Year End Results |
22-Feb-2006 |
| POZEN Announces March 2 Webcast of Fourth Quarter and Year End Results |
16-Feb-2006 |
| Company Profile for POZEN Inc. |
10-Feb-2006 |
| POZEN to Present on Panel at the BIO CEO & Investor Conference |
9-Feb-2006 |
| POZEN Receives Approval for MT 100 in the United Kingdom |
28-Nov-2005 |
| POZEN Names Dr. Everardus Orlemans as Vice President, Clinical Research |
16-Nov-2005 |
| Pozen Announces Dismissal of Derivative Action |
14-Nov-2005 |
| POZEN Names Dr. Elly Savaluny as Vice President, Biostatistics and Data Management |
9-Nov-2005 |
| POZEN Presents Data on PN 100 Combination Product--Designed to Help Prevent NSAID-Induced Gastric Complications; Proof-of-Concept Study Presentation at American College of Gastroenterology (ACG) Annual Meeting |
2-Nov-2005 |
| Pozen Reports Third Quarter 2005 Results; Trexima(TM) NDA Accepted for Filing by FDA in October |
27-Oct-2005 |
| POZEN Announces October 27 Webcast of Third Quarter Results |
13-Oct-2005 |
| GlaxoSmithKline and POZEN Announce Trexima(TM) (Sumatriptan Succinate and Naproxen Sodium) New Drug Application Accepted for Review by FDA |
11-Oct-2005 |
| Pozen to Present at UBS Global Life Sciences Conference |
13-Sep-2005 |
| POZEN Receives Patent on Novel Pain Management/GI Combination Product; Company to Present Study Data at ACG Annual Meeting in November 2005 |
16-Aug-2005 |
| POZEN Submits New Drug Application for Trexima(TM) (Sumatriptan Succinate and Naproxen Sodium) for the Acute Treatment of Migraine |
8-Aug-2005 |
| POZEN Provides Results of FDA Advisory Committee Meeting on MT 100(TM) (Naproxen Sodium and Metoclopramide Hydrochloride) |
5-Aug-2005 |
| POZEN Reports Second Quarter 2005 Results; Trexima(TM) NDA on Track for Q3 2005 Submission |
28-Jul-2005 |
| POZEN Announces July 28 Webcast of Second Quarter Results |
14-Jul-2005 |
| FDA Sets August 4, 2005 for Advisory Committee Meeting to Consider Tardive Dyskinesia Risk with MT 100 |
29-Jun-2005 |
| POZEN Names Dr. William Kelce as Vice President, Pre-Clinical Development |
23-Jun-2005 |
| POZEN Names Lisa Zimmerman Vice President, Quality Assurance |
21-Jun-2005 |
| POZEN to Present at Friedman Billings Ramsey 9th Annual Growth Conference |
25-May-2005 |
| POZEN to Present at UBS Global Pharmaceuticals Conference |
16-May-2005 |
| POZEN Reports First Quarter 2005 Results; Trexima NDA Scheduled for 3Q 2005; Notice of Allowance Received for New Patent Application Describing Gastroprotective NSAID Products |
28-Apr-2005 |
| POZEN Hits All Primary Endpoints in Second Phase III Pivotal Trial for Trexima; NDA Submission Scheduled for 3Q 2005 |
21-Apr-2005 |
| POZEN Announces April 28 Webcast of First Quarter 2005 Results |
14-Apr-2005 |
| POZEN Reports Fourth Quarter and Year End 2004 Results; Completes First Trexima Phase III Study |
28-Feb-2005 |
| Pozen to Present at Wells Fargo Securities Health Care Conference |
25-Feb-2005 |
| POZEN Reports Fourth Quarter and Full-Year 2004 Results |
18-Feb-2005 |
| POZEN To Present at NCINVEST2005 Investor Conference |
7-Feb-2005 |
| POZEN Receives Positive News on MT 100 in the U.K. |
26-Jan-2005 |
| European Patent Issued to POZEN for Treatment of Migraine |
25-Jan-2005 |
| Pozen to Present at Piper Jaffray Health Care Conference |
20-Jan-2005 |
| POZEN Inc. Adopts Stockholder Rights Plan |
12-Jan-2005 |
 |
